These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI; Peacock WF; Bunz TJ; Alberts MJ Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814 [TBL] [Abstract][Full Text] [Related]
6. Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study. Weronska A; Papuga-Szela E; Broniatowska E; Undas A J Cardiovasc Pharmacol; 2021 Nov; 78(5):e743-e748. PubMed ID: 34321399 [TBL] [Abstract][Full Text] [Related]
7. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia. Janion-Sadowska A; Papuga-Szela E; Łukaszuk R; Chrapek M; Undas A J Cardiovasc Pharmacol; 2018 Sep; 72(3):153-160. PubMed ID: 29985282 [TBL] [Abstract][Full Text] [Related]
8. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related]
9. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments. Eek AK; Øie E; Granas AG Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587 [TBL] [Abstract][Full Text] [Related]
11. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. Sivolella S; De Biagi M; Brunello G; Berengo M; Pengo V Odontology; 2015 Sep; 103(3):258-63. PubMed ID: 25656043 [TBL] [Abstract][Full Text] [Related]
12. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465 [TBL] [Abstract][Full Text] [Related]
13. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know. Steed MB; Swanson MT Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related]
15. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system. Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885 [TBL] [Abstract][Full Text] [Related]
16. Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Patti G; Haas S J Cardiovasc Pharmacol; 2020 Oct; 77(1):11-21. PubMed ID: 33060545 [TBL] [Abstract][Full Text] [Related]
17. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data. Terayama Y J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Hernandez I; Zhang Y; Saba S Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318 [TBL] [Abstract][Full Text] [Related]
20. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]